Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 39.7% in February

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 4,100 shares, a drop of 39.7% from the January 31st total of 6,800 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 33,300 shares, the short-interest ratio is currently 0.1 days.

Galmed Pharmaceuticals Stock Down 0.5 %

Galmed Pharmaceuticals stock traded down $0.01 during midday trading on Tuesday, reaching $1.93. The company’s stock had a trading volume of 134,393 shares, compared to its average volume of 690,991. Galmed Pharmaceuticals has a fifty-two week low of $1.63 and a fifty-two week high of $23.80. The company has a market cap of $1.24 million, a P/E ratio of -0.12 and a beta of 0.66. The business has a 50-day simple moving average of $2.78 and a 200-day simple moving average of $3.57.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Galmed Pharmaceuticals in a research note on Tuesday. They issued a “sell” rating on the stock.

Institutional Trading of Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 76.14% of the stock is currently owned by hedge funds and other institutional investors.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.